Stemline Therapeutics (STML) Announces SL-401 Phase 2 BPDCN Trial Results to be Presented at EHA
Tweet Send to a Friend
Stemline Therapeutics, Inc. (Nasdaq: STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
